TLDR: Biotech VC Cure Ventures has hired former executives from Sage Therapeutics, Jeff Jonas and Al Robichaud, as partners. Cure Ventures plans to use their expertise to invest in neuroscience startups. Jonas and Robichaud worked at Sage Therapeutics from 2013 to 2022, and Jonas previously started a biotech incubator with funding from investment giant CBC Group.
Cure Ventures, a Boston-based venture capital firm, has recruited two former executives from Sage Therapeutics to join its team. Jeff Jonas, the former chief executive, and Al Robichaud, the former chief scientific officer, will become partners at Cure Ventures. The firm, which focuses on investing in neuroscience startups, hopes to benefit from the experience and expertise of these former Sage Therapeutics employees. Jonas had previously left Sage Therapeutics to start a biotech incubator, but he left that project in September. Robichaud left Sage Therapeutics around the same time. The two had worked together at Sage Therapeutics for nearly a decade.
Sage Therapeutics recently gained FDA approval for its drug Zurzuvae, which is intended to treat postpartum depression. However, the FDA only approved the drug for postpartum depression and issued a boxed warning label noting the drug’s sedative effects. Despite this setback, Cure Ventures is confident that Jonas and Robichaud will be valuable assets in its efforts to support and invest in neuroscience startups. Cure Ventures was founded in 2021 by three veteran biotech investors and aims to address the unmet medical needs in the field of neuroscience.
